Hepion Pharmaceuticals (HEPA) Ratios
Hepion Pharmaceuticals Ratios
HEPA's free cash flow for Q2 2026 was $-1.39M. For the 2026 fiscal year, HEPA's free cash flow was increased by $4.00 and operating cash flow was $-1.39M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 |
| Quick Ratio | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 |
| Cash Ratio | 6.11 | 0.13 | 2.80 | 6.49 | 11.13 |
| Solvency Ratio | -20.49 | -3.79 | -4.52 | -4.05 | -3.09 |
| Operating Cash Flow Ratio | -10.93 | -5.79 | -7.73 | -4.43 | -3.80 |
| Short-Term Operating Cash Flow Coverage | -60.51 | -6.28 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 2.67M | $ -1.86M | $ 6.67M | $ 46.11M | $ 86.89M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 1.80 | 0.01 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | -1.56 | 0.03 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 2.80 | 0.03 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | -0.87 | 2.49 | 1.21 | 1.11 |
| Debt Service Coverage Ratio | -47.54 | -2.87 | -5161.06 | -4143.29 | -3682.95 |
| Interest Coverage Ratio | -170.60 | -15.51 | -5118.64 | -4475.47 | -3431.91 |
| Debt to Market Cap | 0.10 | 1.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 33.75 | 2.75 | 0.84 | 4.64 |
| Net Debt to EBITDA | 0.48 | -0.17 | 0.30 | 1.14 | 2.79 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 81.63% | 99.17% | 93.60% | 100.00% |
| EBT Per EBIT | 198.81% | 83.54% | 101.83% | 99.11% | 107.63% |
| Return on Assets (ROA) | -269.64% | -817.51% | -270.39% | -70.05% | -31.60% |
| Return on Equity (ROE) | -310.32% | 708.00% | -671.99% | -84.64% | -35.19% |
| Return on Capital Employed (ROCE) | -150.28% | 1264.36% | -378.37% | -86.88% | -31.89% |
| Return on Invested Capital (ROIC) | -147.41% | -1152.84% | -371.87% | -81.24% | -31.80% |
| Return on Tangible Assets | -269.64% | -817.51% | -270.39% | -73.96% | -33.22% |
| Earnings Yield | -1466.24% | -456.61% | -380.29% | -184.35% | -40.84% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.35 | -148.23 | -514.87 | -458.63 | -444.22 |
| Free Cash Flow Per Share | -0.35 | -148.23 | -515.05 | -458.85 | -446.07 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -2858.56 | -2140.13 | -239.44 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -2858.56 | -2140.13 | -239.44 |
| Operating Cash Flow Coverage Ratio | -60.51 | -6.28 | -195.62 | -652.09 | -98.50 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -579.48% | -630.49% | -317.93% | -152.80% | -39.13% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.07 | -0.22 | -0.26 | -0.54 | -2.45 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.21 | -1.55 | 1.77 | 0.46 | 0.86 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.17 | -0.16 | -0.31 | -0.65 | -2.56 |
| Price-to-Operating Cash Flow Ratio | -0.17 | -0.16 | -0.31 | -0.65 | -2.57 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | -0.07 | -0.02 | 0.03 |
| Enterprise Value Multiple | 0.32 | -0.36 | 0.03 | 0.63 | 0.33 |
| Enterprise Value | -1.21M | 5.38M | -1.71M | -28.24M | -10.90M |
| EV to EBITDA | 0.32 | -0.36 | 0.03 | 0.63 | 0.33 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.37 | -0.30 | 0.04 | 0.81 | 0.35 |
| EV to Operating Cash Flow | 0.37 | -0.30 | 0.04 | 0.81 | 0.35 |
| Tangible Book Value Per Share | 0.28 | -15.16 | 91.68 | 612.18 | 1251.00 |
| Shareholders’ Equity Per Share | 0.28 | -15.16 | 91.68 | 654.03 | 1323.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.18 | 0.01 | 0.06 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.88 | -107.35 | -616.07 | -553.60 | -465.52 |
| Tax Burden | 1.00 | 0.82 | 0.99 | 0.94 | 1.00 |
| Interest Burden | 2.20 | 1.08 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.40 | 1.38 | 0.84 | 0.83 | 0.95 |
Currency in USD
